SELLAS Life Sciences (SLS)

• Market cap: $240M
• 1 day: -4.48%
• 5 days: -10.7%
• 1 month: 11.63%
• 3 months: 3.78%
• 6 months: 48.84%
• Year to date: 79.44%
• 1 year: 61.34%
• 5 years: -26.44%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Employees: 15